Oxycodone IR
Phase 3Small molecule
Johnson & JohnsonOxycodone IR is one of 91 small molecule programs targeting Low back pain. It is currently in Phase 3.
4
Indications
9
Total Trials
0
Active Trials
90
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
237 competitors in Low Back Pain
#DrugCompanyPhaseTrials
1Pred Forte
NovartisPhase 3
Suboxone
IIndivior Inc.
Phase 3
Keterol
PPamukkale University
Phase 3
Ultram
Haisco Pharmaceutical Group Co., Ltd.Phase 3
Voltaren
CCerimon Pharmaceuticals
Phase 3
Hydrocodone/acetaminophen
AbbViePhase 3
OROS Oxybutynin
Johnson & JohnsonPhase 3
Cortisone Acetate
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Tapentadol ER
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Zohydro Er
TevaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Opioid Use1 trial
Bone pain1 trial
Oxycodone1 trial
4 more indications
Osteoporosis1 trial
Low back pain1 trial
Joint Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Oxycodone IR. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company